The prevention of major neurocognitive disorders in the next phase of COVID-19 pandemic: On being proactive

Beauchet, Olivier; Allali, Gilles

doi:10.1016/j.maturitas.2022.03.005

Cited by 2 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The inflammatory cascade triggered by SARS-CoV-2 infection involves the secretion of numerous cytokines including tumor necrosis factor (TNFα), a key cytokine in signaling and COVID-19-related protein cascades ( Karki et al, 2021 ). One emerging hypothesis following observations of persistent long-term cognitive difficulties and physiological patterns after COVID-19 suggests a potential trigger or accelerator of neurodegenerative process ( Beauchet and Allali, 2022 , McAlpine et al, 2021 ). Indeed, different studies have shown that COVID-19 associates with neurotoxicity, hippocampal degeneration, and increased risk of Alzheimer's disease ( Bayat et al, 2022 , Chiricosta et al, 2021 , Li et al, 2022 ).…”

Section: Introductionmentioning

confidence: 99%

Acute TNFα levels predict cognitive impairment 6–9 months after COVID-19 infection

Nuber-Champier¹,

Cionca²,

Bréville³

et al. 2023

Psychoneuroendocrinology

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Acute TNFα levels predict cognitive impairment 6–9 months after COVID-19 infection

Nuber-Champier¹,

Cionca²,

Bréville³

et al. 2023

Psychoneuroendocrinology

View full text Add to dashboard Cite

“…Major changes in tissue damage markers in brain areas functionally connected to the primary olfactory cortex were also observed (Douaud et al, 2022 ), which could explain why 29.8% of PACS patients complain of persistent dysosmia, or a change in the sense of smell, more than 24 months after COVID-19 (Lechien et al, 2023 ). The point is that much of the recent literature focuses on the emerging risk of neurodegenerative disease and more precisely on AD (Luukkainen et al, 2018 ; Heneka et al, 2020 ; Rebholz et al, 2020 ; Verkhratsky et al, 2020 ; Erausquin et al, 2021 ; Mahalaxmi et al, 2021 ; Beauchet and Allali, 2022 ; Chen et al, 2022 ) after contracting COVID-19.…”

Section: Introductionmentioning

confidence: 99%

Alzheimer's early detection in post-acute COVID-19 syndrome: a systematic review and expert consensus on preclinical assessments

Vandersteen,

Plonka,

Manera

et al. 2023

Front. Aging Neurosci.

Self Cite

View full text Add to dashboard Cite

IntroductionThe risk of developing Alzheimer's disease (AD) in older adults increasingly is being discussed in the literature on Post-Acute COVID-19 Syndrome (PACS). Remote digital Assessments for Preclinical AD (RAPAs) are becoming more important in screening for early AD, and should always be available for PACS patients, especially for patients at risk of AD. This systematic review examines the potential for using RAPA to identify impairments in PACS patients, scrutinizes the supporting evidence, and describes the recommendations of experts regarding their use.MethodsWe conducted a thorough search using the PubMed and Embase databases. Systematic reviews (with or without meta-analysis), narrative reviews, and observational studies that assessed patients with PACS on specific RAPAs were included. The RAPAs that were identified looked for impairments in olfactory, eye-tracking, graphical, speech and language, central auditory, or spatial navigation abilities. The recommendations' final grades were determined by evaluating the strength of the evidence and by having a consensus discussion about the results of the Delphi rounds among an international Delphi consensus panel called IMPACT, sponsored by the French National Research Agency. The consensus panel included 11 international experts from France, Switzerland, and Canada.ResultsBased on the available evidence, olfaction is the most long-lasting impairment found in PACS patients. However, while olfaction is the most prevalent impairment, expert consensus statements recommend that AD olfactory screening should not be used on patients with a history of PACS at this point in time. Experts recommend that olfactory screenings can only be recommended once those under study have reported full recovery. This is particularly important for the deployment of the olfactory identification subdimension. The expert assessment that more long-term studies are needed after a period of full recovery, suggests that this consensus statement requires an update in a few years.ConclusionBased on available evidence, olfaction could be long-lasting in PACS patients. However, according to expert consensus statements, AD olfactory screening is not recommended for patients with a history of PACS until complete recovery has been confirmed in the literature, particularly for the identification sub-dimension. This consensus statement may require an update in a few years.

show abstract

The prevention of major neurocognitive disorders in the next phase of COVID-19 pandemic: On being proactive

Cited by 2 publications

References 8 publications

Acute TNFα levels predict cognitive impairment 6–9 months after COVID-19 infection

Acute TNFα levels predict cognitive impairment 6–9 months after COVID-19 infection

Alzheimer's early detection in post-acute COVID-19 syndrome: a systematic review and expert consensus on preclinical assessments

Contact Info

Product

Resources

About